CA
NZ
UK
AU
IND
US
Apimeds Pharmaceuticals (NYSE American:APUS) shares are up 29.07% pre-market to $6.35, building on a prior close of $4.92, after the company's subsidiary, MindWave Innovations, signed a 12-month technology services agreement with Singapore-based AQUAE Holdings. Under the deal, MindWave will design, develop, deploy, and host …
Celularity (NASDAQ:CELU) shares are down 1.52% pre-market to $1.30, a modest pullback after the stock closed up 14.78% in the prior session on news of an initial financing closing that generated over $10 million in gross cash proceeds. The closing is part of a …
MediciNova (NASDAQ:MNOV) shares are up 1.89% pre-market to $2.70, building on a prior close of $2.65, after the company announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 trial evaluating MN-166 (ibudilast) for Amyotrophic Lateral …
Nektar Therapeutics (NASDAQ:NKTR) shares are up 5.42% pre-market to $62.60, building on a prior close of $59.38, extending a volatile stretch that included an 8% decline earlier in the week and a research-firm price target cut to $50 from $80. The rebound comes as …
Sunshine Biopharma (NASDAQ:SBFM) shares are up 4.85% pre-market to $0.84, building on a prior close of $0.80, after the company launched generic ondansetron tablets in 4mg and 8mg strengths in the Canadian market. Ondansetron is the generic equivalent of Zofran, a prescription serotonin 5-HT3 …
Scribe Therapeutics Inc. climbed in pre-market trading after coverage reported that Cathie Wood's ARK added to its Scribe Therapeutics position while reducing its Tempus AI holding, giving the early move a company-specific explanation rather than one tied to broader biotechnology activity. ARS Pharmaceuticals, Inc. …
Surrozen, Inc. traded lower after coverage of an FDA submission that opened a path for its lead therapy, alongside reported progress toward an investigational new drug application and a potential financing milestone. The stock's move was more negative than the 0.8% median for peers …
10x Genomics, Inc. rose in premarket trading following a mixed session for comparable biotechnology names, with Bruker Corporation little changed and Avantor, Inc. up 0.7%. TXG's computed move stood above the sector-peer median of 0.3%, and a separate market reference described the move as …
Autonomix Medical's new European patent covers measuring nerve activity in the eye, giving the company a defined protected area within its Medical - Devices business. The grant follows recent attention to the company's European intellectual-property footprint and precision neuromodulation technology, though the verified patent …
Design Therapeutics' shares rose to USD 12.93 pre-market without any confirmed company-specific development to explain the move, leaving it a market-screen event that needs regular-session confirmation rather than a response to an identified catalyst. The pre-market quote stood above the session's USD 11.83 to …
Please wait processing your request...